ECSP18049762A - Nuevos anticuerpos anti-claudina y sus métodos de uso - Google Patents

Nuevos anticuerpos anti-claudina y sus métodos de uso

Info

Publication number
ECSP18049762A
ECSP18049762A ECSENADI201849762A ECDI201849762A ECSP18049762A EC SP18049762 A ECSP18049762 A EC SP18049762A EC SENADI201849762 A ECSENADI201849762 A EC SENADI201849762A EC DI201849762 A ECDI201849762 A EC DI201849762A EC SP18049762 A ECSP18049762 A EC SP18049762A
Authority
EC
Ecuador
Prior art keywords
methods
new anti
claudin antibodies
antibodies
claudin
Prior art date
Application number
ECSENADI201849762A
Other languages
English (en)
Inventor
Vikram Natwarsinhji Sisodiya
Robert A Stull
Sarah Fong
Samuel A Williams
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of ECSP18049762A publication Critical patent/ECSP18049762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proveen nuevos anticuerpos y conjugados de anticuerpo y fármaco anti-CLDN (ADC), incluyendo a derivados de los mismos, y métodos para usar los mismos para tratar trastornos proliferativos.
ECSENADI201849762A 2015-12-04 2018-07-03 Nuevos anticuerpos anti-claudina y sus métodos de uso ECSP18049762A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562263542P 2015-12-04 2015-12-04
US201662427027P 2016-11-28 2016-11-28

Publications (1)

Publication Number Publication Date
ECSP18049762A true ECSP18049762A (es) 2018-07-31

Family

ID=58797837

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201849762A ECSP18049762A (es) 2015-12-04 2018-07-03 Nuevos anticuerpos anti-claudina y sus métodos de uso

Country Status (23)

Country Link
US (1) US20190083645A1 (es)
EP (1) EP3383917A4 (es)
JP (1) JP2019500335A (es)
KR (1) KR20180088445A (es)
CN (1) CN108473588A (es)
AU (1) AU2016364853A1 (es)
BR (1) BR112018011319A2 (es)
CA (1) CA3006738A1 (es)
CL (2) CL2018001481A1 (es)
CO (1) CO2018005752A2 (es)
CR (1) CR20180348A (es)
DO (1) DOP2018000138A (es)
EC (1) ECSP18049762A (es)
HK (1) HK1254743A1 (es)
IL (1) IL259681A (es)
MA (1) MA43385A (es)
MX (1) MX2018006782A (es)
PE (1) PE20181302A1 (es)
PH (1) PH12018501153A1 (es)
RU (1) RU2018124319A (es)
SG (1) SG11201804673WA (es)
TW (1) TW201726175A (es)
WO (1) WO2017096163A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
ES2979068T3 (es) 2016-07-08 2024-09-24 Crage Medical Co Ltd Anticuerpos para anti-claudina 18A2 y utilización de los mismos
BR112020003003A2 (pt) * 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
CR20200145A (es) * 2017-09-02 2020-08-03 Abbvie Inc Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
JP2020532543A (ja) * 2017-09-02 2020-11-12 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
JP2021525265A (ja) * 2018-05-25 2021-09-24 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン複合体
KR20210128443A (ko) 2019-02-15 2021-10-26 인테그럴 몰큘러 인코포레이티드 클라우딘 6 항체 및 이의 용도
DK3941946T3 (da) * 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
TWI856078B (zh) 2019-03-25 2024-09-21 日商第一三共股份有限公司 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途
EP4054648A4 (en) * 2019-11-05 2023-12-27 LaNova Medicines Limited ANTIBODY DRUG CONJUGATES DIRECTED AGAINST CLAUDIN 18.2
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR102451185B1 (ko) * 2021-08-05 2022-10-07 환인제약 주식회사 도네페질 함유 지속방출형 미립구
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
AU2024274880A1 (en) 2023-05-25 2026-01-15 The Regents Of The University Of California Methods of treating cancer
WO2025209525A1 (zh) * 2024-04-03 2025-10-09 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2425309B (en) * 2003-12-31 2008-07-09 Council Scient Ind Res C2-fluoro pyrrolo[2,1-c][1,4]benzodiazepine dimers
US7189710B2 (en) * 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
KR101772354B1 (ko) * 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
KR101645905B1 (ko) * 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
PE20160870A1 (es) * 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso

Also Published As

Publication number Publication date
HK1254743A1 (zh) 2019-07-26
MA43385A (fr) 2018-10-10
AU2016364853A1 (en) 2018-06-21
RU2018124319A (ru) 2020-01-09
CO2018005752A2 (es) 2018-06-12
KR20180088445A (ko) 2018-08-03
BR112018011319A2 (pt) 2018-12-04
MX2018006782A (es) 2018-11-09
CN108473588A (zh) 2018-08-31
WO2017096163A1 (en) 2017-06-08
TW201726175A (zh) 2017-08-01
EP3383917A4 (en) 2019-08-21
SG11201804673WA (en) 2018-06-28
US20190083645A1 (en) 2019-03-21
CA3006738A1 (en) 2017-06-08
PE20181302A1 (es) 2018-08-09
CL2018001481A1 (es) 2018-08-24
EP3383917A1 (en) 2018-10-10
CL2019000189A1 (es) 2019-06-07
IL259681A (en) 2018-07-31
DOP2018000138A (es) 2018-12-31
PH12018501153A1 (en) 2019-01-28
CR20180348A (es) 2018-08-23
JP2019500335A (ja) 2019-01-10

Similar Documents

Publication Publication Date Title
ECSP18049762A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
CO2017010890A2 (es) Derivados de maitansinoide, conjugados del mismo, y metodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
UY36862A (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
BR112016013048A2 (pt) anticorpos anti-dpep3 e métodos de uso
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso